Spain's Zeltia Group Presents Positive Zalypsis Data
MADRID, Oct 23 (Reuters) - Spanish pharmaceutical company Zeltia said on Thursday Phase II trials on Zalypsis and Irvalec show that the drugs are clinically safe and highly active for the treatment of solid tumours or lymphoma.